Cryoport, Inc. (CYRX) stock analysis
Industrials · Integrated Freight & Logistics
From the 10-K filed 2026-03-05
Business type: Asset play
How it makes money
It earns revenue by providing logistics and hardware to life science companies, with growth driven by the expansion of clinical trials.
It operates in two segments: Life Sciences Services, which provides temperature-controlled logistics and storage, and Life Sciences Products, which manufactures cryogenic freezers. Growth in its service segment is tethered to the number of ongoing clinical and commercial cell and gene therapy programs, as these high-value materials require specialized, compliant handling throughout the research and commercialization lifecycle.
What protects it: the moat
It claims to protect its earnings through an integrated digital platform and a proprietary global network.
Management asserts that its competitive advantage lies in its 'Chain of Compliance,' a system that manages chain-of-custody, chain-of-condition, and chain-of-identity. By integrating its logistics with a digital nerve center called Cryoportal, it aims to reduce risk for clients, though the efficacy and proprietary nature of these systems remain management's claims.
What growth costs
It incurs costs for global operations and the procurement of components from third-party manufacturers.
The filing does not provide specific capital expenditure or R&D figures. It notes that it must maintain a global supply chain network and procure components—some sole-sourced—from third-party manufacturers to sustain its services and product manufacturing.
What could damage it
A supply disruption of sole-sourced components would prevent it from delivering solutions, causing immediate customer attrition.
Because it relies on third-party manufacturers for critical components, a manufacturing stoppage—whether from a natural disaster or labor strike—breaks the chain of custody. Since its customers operate in highly regulated environments where therapy viability is paramount, such failures would drive clients to competitors to secure their biological materials.
About Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.